HSV type-specific IgG antibodies are immunoglobulins directed against glycoprotein G (gG-1 for HSV-1 and gG-2 for HSV-2), which are highly type-discriminating envelope proteins that allow serological distinction between the two herpes simplex virus subtypes. These antibodies develop 2–6 weeks after primary infection and persist lifelong, serving as reliable markers of prior or latent HSV infection. Type-specific serology is particularly valuable because clinical presentation alone cannot reliably differentiate HSV-1 from HSV-2 infection. Following primary HSV infection, the adaptive immune system generates type-specific IgG antibodies targeting the unique antigenic regions of gG-1 or gG-2; these antibodies do not reliably cross-react between subtypes, enabling accurate serotyping. HSV establishes latency in sensory ganglia after primary infection, and IgG antibodies remain detectable indefinitely due to ongoing antigenic stimulation from periodic viral reactivation. The presence of type-specific IgG reflects cumulative exposure history rather than active replication, as antibody titers do not reliably correlate with disease activity or reactivation frequency.
This blood test checks whether your immune system has developed antibodies against herpes simplex virus type 1 (HSV-1, commonly associated with oral cold sores) or type 2 (HSV-2, commonly associated with genital herpes). A positive result means you were exposed to that type of herpes virus at some point in your life — the virus stays in your body in an inactive (latent) state, even if you have never had noticeable symptoms. A negative result means you have not been infected with that type and are susceptible to it. Because many people with herpes have no symptoms or very mild ones, this test can help clarify your status for personal health decisions, partner communication, and pregnancy planning. Your healthcare provider can help you understand what the result means for your specific situation.
When elevated: A positive (reactive) HSV-1 or HSV-2 IgG result indicates prior infection with the respective viral type and implies lifelong latent infection with potential for periodic reactivation. For HSV-2, a positive result has significant implications for sexual transmission risk, partner counseling, and, in pregnancy, neonatal herpes prevention strategies. Positive HSV-2 IgG in an asymptomatic individual does not indicate active disease but warrants discussion of transmission risk reduction. When low: A negative (non-reactive) result suggests the individual has not been previously infected with the respective HSV type, indicating susceptibility to primary infection. Negative results are clinically meaningful in the context of pregnancy (identifying serodiscordant couples at risk for primary infection near term) and in immunocompromised patients where seronegativity guides prophylaxis decisions. A negative result within the first 2–6 weeks of a suspected primary infection may represent the seronegative window period and should be repeated if clinical suspicion remains high.
HSV seropositivity has minimal direct relevance to athletic performance or training outcomes. However, understanding your HSV status may inform decisions about oral herpes recurrence triggers (stress, sleep deprivation, intense training phases) and transmission risk in close-contact sports; some athletes find this baseline knowledge useful for managing lifestyle factors that influence viral reactivation.
Fasting Required
No
Order online
Choose your lab and check out. We send your lab requisition automatically — no doctor visit needed.
Get your sample collected
Visit a lab service center near you for a quick blood draw (or book at-home phlebotomy where available).
See your results
Your results land in your Insider portal, ready to review and act on — that easy.
Your price
$60.00$180
3.0× less than retail
Versus the typical direct-to-consumer retail price for this test (illustrative — consumer prices vary by provider and region).
$60.00
Peer-reviewed sources supporting the educational content on this page.